Clinical Trial: Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis

U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT03054610) titled 'Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis' on Feb. 13.
Brief Summary: Plantar fasciitis is the most common cause of plantar heel pain and is commonly present in people 40 years of age or older, overweight, sedentary or with intense physical activity. It is caused by the over-stretching of the plantar fascia, which is a band of connective tissue that extends to the base of the phalanges. This produces micro-tears more commonly in its origin in the medial tuberosity of the calcaneus which causes an inflammatory process and pain. This pain usually occurs when the person gets up in the morning after sleeping or after sitting for a long time. That is when the fascia is stretched after being in a contraction position.
There are a great variety of treatments for this pathology, of these, one of the most common is the use of intralesional steroids, which a weighing that reduces symptomatology in many cases also has undesirable effects such as subcutaneous fat atrophy, rupture of the plantar fascia, peripheral nerve injury, muscle damage and stress fractures. Other treatments are extracorporeal shock waves, application of platelet-rich plasma and application of botulinum toxin A intralesional. All of them are accompanied by insoles, night splints and stretching exercises of the Achilles tendon and the plantar fascia.
Recent studies have shown that the application of botulinum toxin A intralesional in patients with plantar fasciitis helps to improve the symptomatology to decrease pain in both intensity and presentation time. Decreased inflammation of the plantar fascia has also been demonstrated. This is the sale of the usual form of action of the botulinum toxin, which is applied regularly in the muscles to block the release of acetylcholine in the neuromuscular plaque and obtain its relaxation and not directly in the pain points. We believe that the botulinum toxin can be applied intralesional currently, since there is information that the toxin has analgesic and anti-inflammatory effect and not just muscle relaxation.
The aim of our work demonstrate that the use of botulinum toxin A and intralesional stretching exercises is superior to intralesional steroids and stretching trying to establish a safer and less painful therapy avoiding complications prior to the application of steroid application.
Study Start Date: January 2015
Study Type: Interventional
Condition: Plantar Fascitis
Botulinum Toxins, Type A
Intervention: Drug: Betamethason Sodium Phosphate
Other Name: Celestone Soluspan
Drug: Ropivacaine
Other Name: Ropiconest
Drug: Botulinum Toxins, Type A
Other Name: Dysport
Recruitment Status: Recruiting
Sponsor: Universidad Autonoma de Nuevo Leon
Information provided by (Responsible Party): Carlos A Acosta-Olivo, Universidad Autonoma de Nuevo Leon